Evidence

Tamoxifen Therapy Benefit for Patients with 70-gene Signature High and Low Risk

November 1, 2017

PUBLICATION: Breast Cancer Res Treat (2017) 166: 593. https://doi.org/10.1007/s10549-017-4428-9. AUTHORS: Laura J. van ‘t Veer, Christina Yau, Nancy Y. Yu, Christopher C. Benz, Bo Nordenskjöld, Tommy Fornander, Olle Stål, Laura J. Esserman, Linda Sofie Lindström SUMMARY: 20yr BCSS and 10yr DMFS analysis of MammaPrint High Risk vs Low Risk patients in the STO trial. Read more: van’t Veer…

Read more

Gene Expression Profiling of Breast Cancer: A New Tumor Marker

March 10, 2005

PUBLICATION: Journal of Clinical Oncology March 10, 2005 23:8, 1631-1635 AUTHORS: Laura J. van’t Veer, Soonmyung Paik, Daniel F. Hayes SUMMARY: A review of genomic signatures and the genomic landscape. Read more: van’t Veer et al_2005_Journal of Clinical Oncology._Gene Expression Profiling  

Read more

Gene Expression Profiling Predicts Clinical Outcome of Breast Cancer

January 31, 2002

PUBLICATION: Nature. 2002 Jan 31;415(6871):530-6. AUTHORS: van ‘t Veer L.J., Dai H., van de Vijver M.J., He Y.D., Hart A.A., Mao M., Peterse H.L., van der Kooy K., Marton M.J., Witteveen A.T., Schreiber G.J., Kerkhoven R.M., Roberts C., Linsley P.S., Bernards R., Friend S.H. SUMMARY: Development of MammaPrint from 98 tumors, to 78 (non-BRCA). his gene expression profile…

Read more